Navigating the clinical impact of TROP2-targeting in NSCLC

🔬 Expert insights on TROP2-targeted ADCs in NSCLC Stay ahead in the rapidly evolving landscape of non-small cell lung cancer (NSCLC) treatment. Join leading lung cancer specialists Prof. Marina Garassino, Prof. Jarushka Naidoo and Prof. David Planchard as they explore the clinical potential of TROP2-targeted antibody-drug conjugates (ADCs) in NSCLC 🎓 In this activity, gain insights into: ✅ Clinical trial data on three investigational TROP2 ADCs ✅ The role of TROP2 as a biomarker and patient selection strategies ✅ Toxicity management strategies for improved outcomes 🧰 Resources available: 📽️ On-demand expert videos 📑 Presentation slides 🛠️ Practice aid 📺 Watch now to stay updated on the emerging role of TROP2 ADC in NSCLC: https://touchoncologyime.org/trop2-ad... This activity is funded by an independent medical education grant from Daiichi Sankyo and AstraZeneca. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. #NSCLC #TROP2 #LungCancer #ELCC2025 #LungCancerResearch #cancercare #Biomarkers